Fig. 7
From: CD46 targeted 212Pb alpha particle radioimmunotherapy for prostate cancer treatment
89Zr-DFO-YS5 PET imaging of a prostate cancer PDX model. A PET images of PDX, with (right) or without (left) competition with cold YS5 antibody 3Â days post-injection of 89Zr-DFO-YS5 PET. The cold YS5 antibody were administered 2Â days prior to 89Zr-DFO-YS5 in the blocking control group. B Standardized uptake values (SUVs) derived from PET images for tumor and normal organs (hear, liver and muscle). Blue bar: SUV derived from 89Zr-DFO-YS5 PET images without cold YS5. Orange bar: SUV derived from 89Zr-DFO-YS5 PET images with cold YS5